Precision manufacturing for clinical-quality regenerative medicines

Innovations in engineering applied to healthcare make a significant difference to people's lives. Market growth is guaranteed by demographics. Regulation and requirements for good manufacturing practice—extreme levels of repeatability and reliability—demand high-precision process and measurement solutions. Emerging technologies using living biological materials add complexity. This paper presents some results of work demonstrating the precision automated manufacture of living materials, particularly the expansion of populations of human stem cells for therapeutic use as regenerative medicines. The paper also describes quality engineering techniques for precision process design and improvement, and identifies the requirements for manufacturing technology and measurement systems evolution for such therapies.

[1]  R. Preti.  Bringing safe and effective cell therapies to the bedside , 2005, Nature Biotechnology.

[2]  Thomas Becker,et al.  Future aspects of bioprocess monitoring. , 2007, Advances in biochemical engineering/biotechnology.

[3]  Heli Skottman,et al.  Monitoring and analysis of dynamic growth of human embryonic stem cells: comparison of automated instrumentation and conventional culturing methods , 2007, Biomedical engineering online.

[4]  Olga Tura,et al.  Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources , 2007, Journal of Translational Medicine.

[5]  Raffaella Giancola,et al.  Cell Therapy: cGMP Facilities and Manufacturing , 2012, Muscles, ligaments and tendons journal.

[6]  David J. Williams,et al.  Effects of Dynamic Mechanical Forces on Potential Cell Therapy Products in Cold Transportation , 2010 .

[7]  A. Hjerpe,et al.  Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. , 2000, Experimental cell research.

[8]  S. Chandran,et al.  Automated Mechanical Passaging: A Novel and Efficient Method for Human Embryonic Stem Cell Expansion , 2006, Stem cells.

[9]  Michael T. Longaker,et al.  Stem cell differentiation , 2004, Nature Biotechnology.

[10]  M. Berridge,et al.  Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. , 1993, Archives of biochemistry and biophysics.

[11]  D. V. Coleman.  The man who discovered quality , 1994 .

[12]  D. G. Halme,et al.  FDA regulation of stem-cell-based therapies. , 2006, The New England journal of medicine.

[13]  David J. Williams,et al.  Manufacture of a human mesenchymal stem cell population using an automated cell culture platform , 2007, Cytotechnology.

[14]  N. H. Collins.  Product Review, Release, and Administration , 2009 .

[15]  David J. Williams,et al.  Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine. , 2011, British medical bulletin.

[16]  David J. Williams,et al.  The Application of Assembly and Automation Technologies to Healthcare Products , 2006 .

[17]  Mitchell Klausner,et al.  Organotypic human oral tissue models for toxicological studies. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[18]  David J. Williams,et al.  Automated, scalable culture of human embryonic stem cells in feeder‐free conditions , 2009, Biotechnology and bioengineering.

[19]  David J. Williams,et al.  Cell therapies: realizing the potential of this new dimension to medical therapeutics , 2008, Journal of tissue engineering and regenerative medicine.

[20]  Nam P. Suh,et al.  Axiomatic Design: Advances and Applications , 2001 .

[21]  Roger E. Bohn,et al.  From Filing And Fitting to Flexible Manufacturing , 2005 .

[22]  Oliver Brüstle,et al.  Automated maintenance of embryonic stem cell cultures , 2007, Biotechnology and bioengineering.

[23]  Richard Archer,et al.  Why tissue engineering needs process engineering , 2005, Nature Biotechnology.

[24]  Brett W. Bader,et al.  Fluid Mechanics, Cell Distribution, and Environment in Cell Cube Bioreactors , 2003, Biotechnology progress.

[25]  R. J. Thomas,et al.  Automated, serum-free production of CTX0E03: a therapeutic clinical grade human neural stem cell line , 2009, Biotechnology Letters.

[26]  P. Itsykson,et al.  Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.

[27]  Steve Caplin,et al.  Principles Of Design , 2011 .

[28]  Mmpa Marc Vermeulen,et al.  Design for precision : current status and trends , 1998 .

[29]  David J. Williams,et al.  Success in healthcare technology businesses: Coordinating the value milestones of new product introduction, financial stakeholders and business growth , 2006 .

[30]  C. Mason,et al.  A brief definition of regenerative medicine. , 2008, Regenerative medicine.

[31]  S. Reuveny,et al.  Long-term microcarrier suspension cultures of human embryonic stem cells. , 2009, Stem cell research.

[32]  David J. Williams,et al.  Human cell culture process capability: a comparison of manual and automated production , 2009, Journal of tissue engineering and regenerative medicine.

[33]  C. Babbage.  Economy of Machinery and Manufactures , 1832 .

[34]  Regina Brunauer,et al.  Controversial issue: Is it safe to employ mesenchymal stem cells in cell-based therapies? , 2008, Experimental Gerontology.

[35]  Kirsten H Walen,et al.  Budded karyoplasts from multinucleated fibroblast cells contain centrosomes and change their morphology to mitotic cells , 2005, Cell biology international.

[36]  Alistair Elfick,et al.  Optical Spectroscopy for Noninvasive Monitoring of Stem Cell Differentiation , 2010, Journal of biomedicine & biotechnology.

[37]  M W Naing,et al.  Three-dimensional culture and bioreactors for cellular therapies. , 2011, Cytotherapy.

[38]  D J Williams,et al.  Application of process quality engineering techniques to improve the understanding of the in vitro processing of stem cells for therapeutic use. , 2008, Journal of biotechnology.

[39]  Li Li,et al.  Human Embryonic Stem Cells Possess Immune‐Privileged Properties , 2004, Stem cells.

[40]  David McKenna,et al.  Shipping of therapeutic somatic cell products. , 2011, Cytotherapy.

[41]  David J Williams,et al.  Concise Review: Mind the Gap: Challenges in Characterizing and Quantifying Cell- and Tissue-Based Therapies for Clinical Translation , 2010, Stem cells.

[42]  Marlies Brinkmann,et al.  New technologies for automated cell counting based on optical image analysis `The Cellscreen' , 2004, Cytotechnology.

[43]  Ruian Xu,et al.  The bioreactor: a powerful tool for large-scale culture of animal cells. , 2005, Current pharmaceutical biotechnology.